Skip to main content
Top
Published in: Abdominal Radiology 12/2021

01-12-2021 | Computed Tomography | Pancreas

Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?

Authors: Yang Guo, Ferenc Czeyda-Pommersheim, Joseph A. Miccio, Sowmya Mahalingam, Michael Cecchini, Jay Pahade

Published in: Abdominal Radiology | Issue 12/2021

Login to get access

Abstract

Purpose

To investigate if a simplified image based scoring system assessing treatment response after neoadjuvant therapy (NAT) can predict survival in patients with pancreatic ductal adenocarcinoma (PDAC) who achieved subsequent R0 resection.

Methods

Retrospective analysis of 57 PDAC patients (male = 29, 51%) with mean age of 64 at diagnosis (range 42–79) who received NAT and R0 resection. Post-NAT overall, arterial and venous imaging response was characterized as improved, similar, or worse by 2 readers independently followed by consensus review. Kaplan–Meier Analysis was performed to compare overall survival (OS) with post-NAT overall imaging response. A Multivariable Cox proportional hazards analysis was performed to evaluate the association of the following variables with OS: overall, arterial and venous radiology response, clinical staging, postoperative CA19-9, and patient age.

Results

At study conclusion, 30/57 patients were deceased (53%), 26/57 (46%) alive, and 1 patient unknown. Post-NAT, 39/57 (68.4%) had overall improved disease and 18/57 (31.6%) had similar disease. The median OS was 55.7 months (95% CI 33.4–not reached, NR) for those with improved disease vs. 53.9 months (95% CI 14.3–NR) with similar disease (p = 0.859) after NAT. Among all clinical parameters, only post-operative CA 19-9 level was associated with OS (p = 0.002) and PFS (p = 0.005), respectively.

Conclusion

Pancreatic cancer patients who underwent R0 resection showed no difference in survival when comparing those with similar vs improved disease on post-NAT imaging.
Literature
1.
go back to reference Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.CrossRef Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.CrossRef
2.
go back to reference Simoes, P.K., et al., Epidemiology of pancreatic adenocarcinoma. Chin Clin Oncol, 2017. 6(3): p. 24.CrossRef Simoes, P.K., et al., Epidemiology of pancreatic adenocarcinoma. Chin Clin Oncol, 2017. 6(3): p. 24.CrossRef
3.
go back to reference McGuigan, A., et al., Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol, 2018. 24(43): p. 4846-4861.CrossRef McGuigan, A., et al., Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol, 2018. 24(43): p. 4846-4861.CrossRef
4.
go back to reference van Veldhuisen, E., et al., Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers (Basel), 2019. 11(7). van Veldhuisen, E., et al., Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers (Basel), 2019. 11(7).
5.
go back to reference Ducreux, M., et al., Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2015. 26 Suppl 5: p. v56-68.CrossRef Ducreux, M., et al., Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2015. 26 Suppl 5: p. v56-68.CrossRef
6.
go back to reference Versteijne, E., et al., Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol, 2020. 38(16): p. 1763-1773.CrossRef Versteijne, E., et al., Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol, 2020. 38(16): p. 1763-1773.CrossRef
7.
go back to reference Versteijne, E., et al., Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials, 2016. 17(1): p. 127.CrossRef Versteijne, E., et al., Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials, 2016. 17(1): p. 127.CrossRef
8.
go back to reference Ghaneh, P., et al., The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg, 2019. 269(3): p. 520-529.CrossRef Ghaneh, P., et al., The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg, 2019. 269(3): p. 520-529.CrossRef
9.
go back to reference Daamen, L.A., et al., Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Eur J Surg Oncol, 2020. Daamen, L.A., et al., Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Eur J Surg Oncol, 2020.
10.
go back to reference Kaltenmeier, C., et al., Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. J Gastrointest Surg, 2020. Kaltenmeier, C., et al., Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. J Gastrointest Surg, 2020.
11.
go back to reference Tummers, W.S., et al., Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg, 2019. 106(8): p. 1055-1065.CrossRef Tummers, W.S., et al., Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg, 2019. 106(8): p. 1055-1065.CrossRef
12.
go back to reference Tempero, M.A., et al., Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw, 2019. 17(3): p. 202–210. Tempero, M.A., et al., Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw, 2019. 17(3): p. 202–210.
13.
go back to reference Hue, J.J., et al., Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Am J Surg, 2020. Hue, J.J., et al., Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Am J Surg, 2020.
14.
go back to reference Murphy, J.E., et al., Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol, 2018. 4(7): p. 963-969.CrossRef Murphy, J.E., et al., Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol, 2018. 4(7): p. 963-969.CrossRef
15.
go back to reference Wolfe, A.R., et al., Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med, 2020. 9(13): p. 4711-4723.CrossRef Wolfe, A.R., et al., Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med, 2020. 9(13): p. 4711-4723.CrossRef
16.
go back to reference Reni, M., et al., Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol, 2017. 28(11): p. 2786-2792.CrossRef Reni, M., et al., Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol, 2017. 28(11): p. 2786-2792.CrossRef
17.
go back to reference Janssen, Q.P., et al., Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer, 2021. 21(1): p. 300.CrossRef Janssen, Q.P., et al., Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer, 2021. 21(1): p. 300.CrossRef
18.
go back to reference Wang, Z.J., et al., Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol (NY), 2020. 45(12): p. 4273-4289.CrossRef Wang, Z.J., et al., Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol (NY), 2020. 45(12): p. 4273-4289.CrossRef
19.
go back to reference Joo, I., et al., Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. AJR Am J Roentgenol, 2018. 210(5): p. 1059-1065.CrossRef Joo, I., et al., Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. AJR Am J Roentgenol, 2018. 210(5): p. 1059-1065.CrossRef
20.
go back to reference Wagner, M., et al., CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol, 2017. 27(7): p. 3104-3116.CrossRef Wagner, M., et al., CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol, 2017. 27(7): p. 3104-3116.CrossRef
21.
go back to reference Cassinotto, C., A. Sa-Cunha, and H. Trillaud, Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging, 2016. 97(12): p. 1225-1232.CrossRef Cassinotto, C., A. Sa-Cunha, and H. Trillaud, Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging, 2016. 97(12): p. 1225-1232.CrossRef
22.
go back to reference Ferrone, C.R., et al., Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg, 2015. 261(1): p. 12-7.CrossRef Ferrone, C.R., et al., Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg, 2015. 261(1): p. 12-7.CrossRef
23.
go back to reference Chang, S.T., et al., Preoperative Multidetector CT Diagnosis of Extrapancreatic Perineural or Duodenal Invasion Is Associated with Reduced Postoperative Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Preliminary Experience and Implications for Patient Care. Radiology, 2016. 281(3): p. 816-825.CrossRef Chang, S.T., et al., Preoperative Multidetector CT Diagnosis of Extrapancreatic Perineural or Duodenal Invasion Is Associated with Reduced Postoperative Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Preliminary Experience and Implications for Patient Care. Radiology, 2016. 281(3): p. 816-825.CrossRef
24.
go back to reference Roche, C.J., et al., CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol, 2003. 180(2): p. 475-80.CrossRef Roche, C.J., et al., CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol, 2003. 180(2): p. 475-80.CrossRef
25.
go back to reference Diehl, S.J., et al., Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology, 1998. 206(2): p. 373-8.CrossRef Diehl, S.J., et al., Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology, 1998. 206(2): p. 373-8.CrossRef
26.
go back to reference Al-Hawary, M.M., et al., Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology, 2014. 270(1): p. 248-60.CrossRef Al-Hawary, M.M., et al., Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology, 2014. 270(1): p. 248-60.CrossRef
27.
go back to reference Crewson, P.E., Reader agreement studies. AJR Am J Roentgenol, 2005. 184(5): p. 1391-7.CrossRef Crewson, P.E., Reader agreement studies. AJR Am J Roentgenol, 2005. 184(5): p. 1391-7.CrossRef
28.
go back to reference Imbriaco, M., et al., Dual-phase versus single-phase helical CT to detect and assess resectability of pancreatic carcinoma. AJR Am J Roentgenol, 2002. 178(6): p. 1473-9.CrossRef Imbriaco, M., et al., Dual-phase versus single-phase helical CT to detect and assess resectability of pancreatic carcinoma. AJR Am J Roentgenol, 2002. 178(6): p. 1473-9.CrossRef
29.
go back to reference Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817-25.CrossRef Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 364(19): p. 1817-25.CrossRef
30.
go back to reference Conroy, T., et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med, 2018. 379(25): p. 2395-2406.CrossRef Conroy, T., et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med, 2018. 379(25): p. 2395-2406.CrossRef
31.
go back to reference Cecchini, M., et al., A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 2020. 49(7): p. 904-911.CrossRef Cecchini, M., et al., A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 2020. 49(7): p. 904-911.CrossRef
32.
go back to reference Cassinotto, C., et al., An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol, 2013. 82(4): p. 589-93.CrossRef Cassinotto, C., et al., An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol, 2013. 82(4): p. 589-93.CrossRef
33.
go back to reference Katz, M.H., et al., Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer, 2012. 118(23): p. 5749-56.CrossRef Katz, M.H., et al., Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer, 2012. 118(23): p. 5749-56.CrossRef
34.
go back to reference Dudeja, V., et al., Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB (Oxford), 2013. 15(9): p. 661-7.CrossRef Dudeja, V., et al., Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB (Oxford), 2013. 15(9): p. 661-7.CrossRef
35.
go back to reference Cassinotto, C., et al., Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology, 2014. 273(1): p. 108-16.CrossRef Cassinotto, C., et al., Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology, 2014. 273(1): p. 108-16.CrossRef
36.
go back to reference Joo, I., et al., Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement. Radiology, 2019. 293(2): p. 343-349.CrossRef Joo, I., et al., Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement. Radiology, 2019. 293(2): p. 343-349.CrossRef
Metadata
Title
Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?
Authors
Yang Guo
Ferenc Czeyda-Pommersheim
Joseph A. Miccio
Sowmya Mahalingam
Michael Cecchini
Jay Pahade
Publication date
01-12-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 12/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03284-5

Other articles of this Issue 12/2021

Abdominal Radiology 12/2021 Go to the issue

Special Section: Young Professionals in Abdominal Radiology: Perspectives

Mosaic mentoring: finding the right mentor for the issue at hand

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.